Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Short Interest Update

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 501,100 shares, a decline of 47.5% from the November 15th total of 953,700 shares. Based on an average daily trading volume, of 1,100 shares, the days-to-cover ratio is currently 455.5 days.

Analyst Upgrades and Downgrades

RCDTF has been the topic of a number of research analyst reports. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Trading Down 1.2 %

OTCMKTS RCDTF traded down $0.64 during trading on Friday, hitting $51.61. The company’s stock had a trading volume of 1 shares, compared to its average volume of 239. Recordati Industria Chimica e Farmaceutica has a 52 week low of $52.25 and a 52 week high of $52.25. The firm has a 50 day moving average price of $52.21 and a 200 day moving average price of $52.02. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.95 and a current ratio of 1.36.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.